| Ticker Details |
Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.
|
| IPO Date: |
October 1, 2002 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$371.13M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.16 | 4.36%
|
| Avg Daily Range (30 D): |
$0.21 | 5.43%
|
| Avg Daily Range (90 D): |
$0.17 | 5.43%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.36M |
| Avg Daily Volume (30 D): |
.42M |
| Avg Daily Volume (90 D): |
.46M |
| Trade Size |
| Avg Trade Size (Sh.): |
240 |
| Avg Trade Size (Sh.) (30 D): |
109 |
| Avg Trade Size (Sh.) (90 D): |
106 |
| Institutional Trades |
| Total Institutional Trades: |
55 |
| Avg Institutional Trade: |
$2.28M |
| Avg Institutional Trade (30 D): |
$10.64M |
| Avg Institutional Trade (90 D): |
$10.64M |
| Avg Institutional Trade Volume: |
.46M |
| Avg Institutional Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.62M |
| Avg Closing Trade (30 D): |
$19.97M |
| Avg Closing Trade (90 D): |
$19.97M |
| Avg Closing Volume: |
1.05M |
|
|
| Financials |
| |
TTM |
Q2 2026 |
Q1 2026 |
|
Basic EPS
|
$-.43
|
$-.14
|
$-.08
|
|
Diluted EPS
|
$-.43
|
$-.14
|
$-.08
|
|
Revenue
|
$M
|
$M
|
$M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-27.84M
|
$-9.11M
|
$-5.05M
|
|
Operating Income / Loss
|
$-15.62M
|
$-3.98M
|
$-4.08M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$M
|
$M
|
$M
|
|
PE Ratio
|
|
|
|
|
|
|
